You are here: Industry Insights > generics

News List

Wockhardt receives US FDA approval for leukemia drug expressbpd
January 22, 2019
The drug stops cancer cells from growing and is indicated for treating cancers like leukemia and some gastro-intestinal tumors
The 20 most expensive pharmacy drugs in 2018, featuring names big and small fiercepharma
January 02, 2019
More and more, specialty drugs carrying eye-popping price tags are winning FDA approvals.
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan fiercepharma
December 19, 2018
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities split between the U.S. and Japan.
Federal Equipment & Investor Group Purchase Pharma Campus contractpharma
December 17, 2018
Capital Recovery Group, Federal Equipment Company, Heritage Global Partners, and PPL Group LLC have jointly finalized the complete purchase of a flexible pharmaceutical manufacturing and packaging
Generics 'cartel' probe expands to a whopping 300 drugs: report fiercepharma
December 11, 2018
Years into a government probe over alleged generic drug price fixing, investigators have expanded the scope to include 300 drugs and 16 companies, an official told The Washington Post.
Mallinckrodt to split business pharmatimes
December 10, 2018
UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company.
Johnson & Johnson shares swoon as pharma giant loses yet another fight to protect Zytiga sales fiercepharma
December 10, 2018
Johnson & Johnson lost its latest effort to fend off Zytiga generics in court, sending investors reeling at the prospect of losing blockbuster sales. But the pharma giant says it’s now planning
J&J shares fall after court refuses to block Zytiga generics pharmaphorum
November 27, 2018
Johnson & Johnson’s share price took a beating this week after the US appeals court declined its bid to stop sales of cheap generic versions of its blockbuster prostate cancer drug Zytiga.
Ranbaxy retains grip on generics market October 24, 2018
BioSpectrum Asia Top 20 Survey Rank 5 - Ranbaxy, India
Generics, small molecule injectables to drive growth, says Piramal biospectrumasia
October 23, 2018
Small molecule injectables are likely to expand at a faster rate'Singapore:India's Piramal Enterprises' Phar

Previous page 1 2 3 4 5 6 Next page